SOM230: A New Therapeutic Modality for Cushing's Disease
DOI:
https://doi.org/10.2533/chimia.2014.483Keywords:
Cushing's disease, Medicinal chemistry, Som230, SomatostatinAbstract
A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high affinity binding to human somatostatin receptors (sst1-5). This unique receptor subtype binding profile, in particular the exceptional high affinity binding to sst5, led to SOM230 being approved by EMEA and FDA in 2012 as the first effective pituitary directed therapeutic modality for Cushing's disease.Downloads
Published
2014-08-27
Issue
Section
Scientific Articles
License
Copyright (c) 2014 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
[1]
Chimia 2014, 68, 483, DOI: 10.2533/chimia.2014.483.